AIMS Neuroscience is an esteemed open-access journal published by the American Institute of Mathematical Sciences (AIMS), dedicated to advancing the field of neuroscience since its inception in 2014. With a robust ISSN of 2373-8006 and an E-ISSN of 2373-7972, this journal aims to provide a platform for innovative research and scholarly discourse that spans the diverse and dynamic landscape of the neuroscience discipline. As of 2023, it holds a respectable Q3 category ranking in the miscellaneous neuroscience field and ranks #65 out of 113 in general neuroscience according to Scopus, positioning it in the 42nd percentile for impact. AIMS Neuroscience encompasses a broad scope of topics, from neurobiology and cognitive neuroscience to computational models and neuroengineering, making it a vital resource for researchers, professionals, and students alike. The journal's commitment to open access ensures that cutting-edge research is freely available, fostering collaboration and knowledge sharing within the global neuroscience community.

NEUROLOGICAL SCIENCES, published by SPRINGER-VERLAG ITALIA SRL, is a premier journal that has been a cornerstone in the field of neurology and related disciplines since its inception in 1996. With an impressive Q1 ranking in Dermatology and Q2 rankings in Neuroloy (clinical) as well as Psychiatry and Mental Health, this journal consistently delivers high-quality peer-reviewed research that informs and shapes clinical practice. The journal boasts a significant presence on Scopus, positioned in the 89th percentile for Dermatology, 73rd for Psychiatry and Mental Health, and 72nd for Neurology (clinical), reflecting its influential contributions to medical knowledge. Open Access options are available, ensuring that this valuable research is accessible to a wider audience committed to advancing their understanding of neurological sciences. As it converges into future years (2024 and beyond), NEUROLOGICAL SCIENCES aims to continue foster collaboration and innovation amongst researchers, professionals, and students within the neurology and mental health domains, making it an indispensable resource for those dedicated to improving patient outcomes and advancing scholarly dialogue.

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS is a distinguished peer-reviewed journal published by KARGER, based in Switzerland. With a focus on the critical fields of cognitive neuroscience, geriatrics, and psychiatry, this journal is integral to advancing our understanding of cognitive decline and geriatric health. Despite being established from 1990 through 1992 and relaunching its scope in 1994, it has consistently provided a platform for innovative research, as reflected in its strong impact factor and notable Scopus rankings, placing it in the Q2 quartile for disciplines including cognitive neuroscience and geriatric medicine. The journal aims to foster interdisciplinary dialogue and collaboration among researchers, healthcare professionals, and educators, contributing to the growing field of dementia research and elderly care. Open access options further ensure that this vital knowledge is widely accessible, making a significant impact in both academic and clinical settings. With a commitment to quality and relevance, DEMENTIA AND GERIATRIC COGNITIVE DISORDERS remains a key resource for those dedicated to understanding and addressing the challenges posed by cognitive disorders in aging populations.

Translational Neurodegeneration, an esteemed journal in the field of neuroscience, is published by BMC and has been an open access platform since 2012, delivering high-quality research from its base in the United Kingdom. With an impressive impact factor reflecting its significant contributions, this journal focuses on critical advancements in cellular and molecular neuroscience, cognitive neuroscience, and clinical neurology, boasting a Q1 ranking across all these categories as of 2023. Researchers and professionals benefit from its extensive reach, characterized by exceptional Scopus rankings that place it in the top percentile of its field. The journal serves as a vital resource for academics and healthcare practitioners alike, aiming to bridge the gap between laboratory discoveries and clinical applications, thereby enhancing understanding and treatment of neurodegenerative diseases. With its commitment to open access, Translational Neurodegeneration ensures that its published research is accessible to a global audience, promoting collaboration and knowledge exchange within the scientific community.

Journal of Alzheimer's Disease, published by IOS Press, stands as a pivotal resource in the fight against Alzheimer's and related neurodegenerative disorders. With an ISSN of 1387-2877 and an E-ISSN of 1875-8908, this esteemed journal has evolved since its inception in 1998, providing a vital platform for academic research and clinical practice in the realms of Clinical Psychology, Geriatrics and Gerontology, Neuroscience, and Psychiatry and Mental Health. Ranked in the Q1 category across several disciplines, including Clinical Psychology and Geriatrics, this journal not only highlights significant advancements in understanding Alzheimer's disease but also fosters interdisciplinary dialogue among researchers, healthcare professionals, and policymakers. Boasting robust Scopus rankings—such as 49th in Clinical Psychology and 29th in Geriatrics—this journal is committed to disseminating high-quality research that informs both therapeutic strategies and public health initiatives. The Journal of Alzheimer's Disease is an essential resource for anyone dedicated to exploring the complexities of cognitive decline and enhancing care for affected individuals.

NEUROLOGIST, an esteemed journal published by Lippincott Williams & Wilkins, serves as a vital resource in the fields of Neurology and Medicine. With an ISSN of 1074-7931 and an E-ISSN of 2331-2637, this journal has been dedicated to advancing the understanding of neurological disorders since its inception in 1996, with continual contributions through 2024. Achieving a respectable Q3 rank in both Medicine (miscellaneous) and Neurology (clinical), it provides an essential platform for disseminating innovative research and clinical studies. Although it is not an open-access publication, NEUROLOGIST promotes a rich exchange of ideas and findings for researchers, healthcare professionals, and students alike, helping to bridge the gaps in neurological research and practice. The journal is recognized for its commitment to enhancing clinical practice and research methodology, making it a valuable asset for anyone engaged in the dynamic field of neurology.

NEUROBIOLOGY OF DISEASE is a premier journal dedicated to advancing the understanding of neurological disorders and the underlying biological processes, published by Academic Press Inc, Elsevier Science. With an impressive impact factor indicative of its significance—ranked in the Q1 quartile in Neurology for 2023 and occupying the 14th rank out of 192 journals in the field of Neuroscience and Neurology—this journal serves as a critical resource for researchers, clinicians, and students alike. The journal has a rich history since its inception in 1994, continuously evolving its scope to encompass groundbreaking research and insights into neurobiological mechanisms and disease pathology. Though it currently does not provide Open Access options, NEUROBIOLOGY OF DISEASE remains a vital vessel for disseminating knowledge that significantly contributes to the field of neurology, fostering an understanding that can lead to innovative therapeutic strategies.

Alzheimer's & Dementia: Translational Research & Clinical Interventions, published by WILEY, is a premier open-access journal that has been at the forefront of innovations in the field of neurology and psychiatry since its inception in 2015. With an impressive impact factor reflecting its high-quality research contributions, this journal has been designated as Q1 in both Neurology (Clinical) and Psychiatry and Mental Health categories for 2023, ranking in the top percentiles of their respective Scopus fields. The journal aims to bridge the gap between research and clinical practice, promoting the translation of scientific discoveries into real-world applications for Alzheimer's disease and other dementias. Positioned in the United States, it is a valuable resource for researchers, clinicians, and students dedicated to advancing knowledge and treatment approaches in these critical areas. With its commitment to open access, the journal ensures that vital research is accessible to a broad audience, fostering collaboration and knowledge sharing across the global scientific community.

npj Aging and Mechanisms of Disease is a leading open-access journal dedicated to advancing the understanding of the biological mechanisms underlying aging and age-related diseases. Published by NATURE PORTFOLIO in the United Kingdom, this journal has established itself as a vital resource within the fields of Aging and Geriatrics and Gerontology, proudly holding a prestigious Q1 ranking in both categories as of 2023. With an impressive Scopus ranking, placing it in the top 10 for Geriatrics and Gerontology, and the top 9 for Aging, the journal is committed to disseminating high-quality, peer-reviewed research that offers innovative insights and fosters collaboration among researchers and practitioners. Since its inception in 2015, npj Aging and Mechanisms of Disease has embraced the open-access model, ensuring that groundbreaking findings are freely available to all, thereby promoting widespread knowledge-sharing within the scientific community. This journal serves as an essential platform for those seeking to explore the complex interplay of genetic, molecular, and environmental factors that influence aging and its associated challenges.

The Lancet Neurology is a premier academic journal published by Elsevier Science Inc, specializing in the field of neurology. With a robust impact factor that signifies its authoritative presence, it consistently ranks in the Q1 category for clinical neurology according to the 2023 standards, positioning itself as the leading journal in its domain, ranking #1 out of 400 in Scopus' neurology rankings and placing in the 99th percentile. Since its establishment in 2002, it has provided a vital platform for disseminating innovative research and clinical advances related to neurological disorders. The journal’s precise focus includes cutting-edge studies on neurodegenerative diseases, stroke, epilepsy, and neuroimaging, which are essential for advancing clinical practice and improving patient outcomes. While it does not offer open access, readers can find high-impact research published monthly, making it indispensable for practitioners, researchers, and students eager to stay at the forefront of neurological science.